icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Renewal of inclusion
Clinical Benefit
Substantial
The actual benefit of DOTAREM remains substantial.
Clinical Added Value
minor
DOTAREM offers a minor improvement in actual benefit (level IV) in terms of safety over gadolinium-based contrast media presenting a high (OMNISCAN, MAGNEVIST) or moderate (MULTIHANCE) risk of nephrogenic systemic fibrosis according to the European Medicines Agency classification.
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
pmHQ7S563qwZ9YNY